Real-world evidence is clinical evidence derived from the analysis of real-world data collected during routine healthcare delivery, including electronic health records, insurance claims, disease registries, and patient-reported outcomes. In regulatory submissions, post-market surveillance reports, and market-access dossiers, it complements randomized controlled trial data by describing how a product performs in broader patient populations and everyday clinical practice outside controlled research settings.
In translation and localization, real-world evidence content appears in post-market surveillance summaries, observational study protocols, market-access dossiers, payer communication materials, and regulatory responses. Translators must preserve distinctions between real-world data and real-world evidence, keep endpoint definitions stable, and adapt epidemiological terms while maintaining the registry or database names used in each market.
A frequent mistake is translating real-world evidence as if it were equivalent to randomized controlled trial evidence, or using the same term for real-world data and real-world evidence. This can mislead reviewers about the strength of conclusions. Another error is rendering registry names or endpoint definitions inconsistently across documents, which makes cross-file comparisons unreliable.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →